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We present a large family with a previously undescribed condition: X-linked dominant congenital bilateral isolated
ptosis. Linkage analysis defined a critical region between Xq24 and Xq27.1, with a maximum single-point LOD
score of 2.88 at DXS1047 and DXS984. Male and female family members are equally affected, providing an
example of an X-linked, truly dominant condition.
The word “ptosis,” an abbreviation for the term “ble-
pharoptosis,” is used to describe the drooping of the
upper eyelid. Ptosis may be congenital or acquired, and
it may be unilateral or bilateral. It can occur in isolation
or in syndromic form, and it is a feature of many con-
ditions. Here, we discuss dominantly inherited congen-
ital isolated ptosis. Work by Engle et al. (1997) on a
pedigree with this condition, first described by Cohen
(1972), has demonstrated linkage to markers in the re-
gion of 1p32-1p34.1 (MIM 178300) with a maximum
two-point LOD score of 8.8. We describe the analysis
of an independent large pedigree with dominant con-
genital isolated ptosis and linkage to the X chromosome.
A family whose members had congenital ptosis was
noted by one of us (A.G.T.), who came across the family
as part of his oculoplastic practice. We made a detailed
assessment of the phenotype of members of this family
willing to participate in the study. The pedigree is that
of a white family from the southwest of England. Mem-
bers of the pedigree exhibit dominantly inherited con-
genital isolated bilateral ptosis, as shown in figure 1. In
particular, there was no evidence of blepharophimosis,
epicanthus inversus, or prevailing ocular motility dis-
order. The ptosis was strikingly symmetrical and equal
in both male and female family members (fig. 1A,B).
The affected family members were born with bilateral
Received September 28, 1999; accepted for publication January 24,
2000; electronically published March 14, 2000.
Address for correspondence and reprints: Dr. T. F. W. McMullan,
Wessex Regional Genetics Laboratory, Salisbury District Hospital,
Salisbury, Wiltshire SP2 8BJ, United Kingdom. E-mail: TFWMCM
@aol.com
 2000 by The American Society of Human Genetics. All rights reserved.
0002-9297/2000/6604-0032$02.00
ptosis, which resulted in an abnormally low lid position
that almost impinges on the visual axis in the primary
position of gaze (superior margin–reflex distance of ∼0
mm). Patients had minimal levator function bilaterally
(!5 mm), associated with an absent upper-lid skin crease.
They had pronounced frontalis overaction and a char-
acteristic chin-up head posture. Best corrected visual
acuity showed no evidence of amblyopia in any patient
studied. Ocular motility was normal in most affected
individuals, but there was reduced upgaze in some af-
fected family members—individuals I:2, II:8, II:21, III:
8, and III:26 (fig. 2). The patients had a good Bell’s
response. No patients reported progression or variability
of their ptosis; for this reason, myasthenia gravis is un-
likely, and edrophonium testing and electromyographic
studies were not performed.
The portion of the pedigree available for study
spanned four generations; 15 affected and 17 unaffected
individuals were available for analysis, including 19 in-
dividuals that are potentially informative for the X chro-
mosome (fig. 2). All procedures were undertaken with
the patients’ informed consent and with ethical approval
from the Salisbury Research Ethics Committee.
We obtained blood and extracted DNA from family
members for linkage analysis. We performed PCR am-
plification under standard conditions. Primers were ob-
tained (MWG-BIOTECH AG) according to sequences
obtained from the Medical Research Council linkage-
mapping set (Reed et al. 1994) supplemented by markers
from the Genome Database. One primer of each pair
was labeled with a fluorochrome at the 5′ end. Hotstar
Taq reagents were used (Qiagen) in the following re-
actions, per sample: 1 ml DNA (100 mg/ml); 0.1 ml (0.5
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Figure 1 A, Female member of the pedigree showing phenotype. B, Male member of the pedigree showing phenotype.
U) Hotstar Taq polymerase; 2 ml 10# PCR buffer; 2 ml
100 mM dNTP; 13.9 ml dH20; and 1 ml each primer (33
ng/ml). Typical thermocycling parameters were as fol-
lows: 15 min at 94C, followed by 32 cycles of 1 min
at 94C, 1 min at 55C, and 1 min at 72C, followed
by 2 min at 72C and 60 min at 60C, and a 4C soak.
We used the following primer pairs to test for linkage
to the chromosome 1 locus: D1S2733, D1S2677,
D1S2797, D1S2134, D1S2824, D1S1616, and
D1S2748. PCR reaction products were separated by
polyacrylamide gel electrophoresis on an ABI 377 an-
alyzer. GENESCAN and GENOTYPER software (ABI)
were used to genotype the individuals. For chromosome
1, we typed seven markers and performed single-point
analysis by MLINK, assuming penetrances to be 90%.
We estimated allele frequencies for the seven markers
from the pedigree.
The results of linkage analysis for chromosome 1 (ta-
ble 1) show no single-point LOD scores to support link-
age of the condition to markers in the region of interest
on chromosome 1, as defined by Engle et al. (1997).
LOD scores of 3.22 and 1.80 for markers D1S2733
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Table 1
Single-Point LOD Scores for Chromosome 1 Markers
PRIMER
LOD AT v
0 .1 .2 .3 .4
D1S2733 3.22 1.16 .50 .18 .04
D1S2677 3.09 1.97 1.08 .49 .14
D1S2797 5.15 2.49 1.33 .62 .20
D1S2134 5.51 2.75 1.80 1.02 .40
D1S2824 1.81 1.67 1.20 .61 .21
D1S1616 1.54 1.52 1.18 .63 .23
D1S2748 1.80 1.54 1.38 .95 .38
Figure 2 Ptosis pedigree with haplotypes. Plus signs () denote samples obtained for analysis; blackened symbols denote affected status.
and D1S2748, which are at either end of their critical
region, exclude linkage to these markers in the pedigree
that we studied. We obtained a LOD value of3.09 for
D1S2677, the marker with the highest LOD score in the
pedigree that they describe. Single-point tests were re-
peated with equal allele frequencies. This was found to
have little effect on the LOD scores. The largest changes
were for D1S2677, where the LOD at recombination
fraction (v) 0 changed from 3.09 to 3.21, and at
D1S2824, where the LOD at changed from1.81v = 0
to 1.62.
The mode of inheritance in our pedigree was such that
no male-to-male transmission was observed in the wider
pedigree (fig. 3), including individuals unavailable for
study; all six sons of affected men were unaffected. How-
ever, the four daughters of affected men were affected.
This is consistent with an X-linked dominant mode of
inheritance. We calculated a LOD score for X linkage
by means of the pedigree alone without haplotype data.
Since women who transmit ptosis are not informative
(their X chromosomes cannot be distinguished without
markers), only the men who transmit ptosis are useful
in this respect. There are a total of six normal sons and
four affected daughters from affected fathers in the wider
pedigree, including individuals unavailable for study (fig.
3). There are thus 10 meioses (not including the index
case) that are consistent with disease linkage to the X
chromosome corresponding to a LOD of 10log102 =
3.01.
We therefore searched for linkage to polymorphic
markers on the X chromosome by means of the methods
described earlier. We used the following markers: HU-
MAR, DXS8092, DXS990, DXS8063, DXS1220,
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Table 2
X-Chromosome LOD Scores
PRIMER
SINGLE-POINT LOD AT v
MULTIPOINT
LOD.0 .1 .2 .3 .4
HUMAR 4.70 2.20 1.18 .53 .16 4.70
DXS8092 3.50 2.09 1.21 .60 .21 3.50
DXS990 2.19 1.30 .72 .35 .12 2.79
DXS8063 1.63 .46 .01 .14 .08 1.61
DXS1220 .97 1.35 1.28 .96 .45 .97
DXS1001 1.92 2.01 1.73 1.24 .59 1.84
DXS425 2.62 2.46 2.03 1.42 .66 2.87
DXS1212 2.70 2.23 1.72 1.13 .48 2.88
DXS8068 2.52 2.08 1.60 1.05 .44 2.88
DXS1047 2.88 2.67 2.19 1.53 .72 2.88
DXS994 .31 .53 .54 .44 .26 2.85
DXS8094 .37 .58 .59 .48 .28 2.78
DXS8050 .32 .46 .46 .38 .23 2.78
DXS1062 .27 .49 .51 .42 .25 2.75
DXS1192 .31 .53 .54 .44 .26 2.69
DXS984 2.88 2.59 2.10 1.46 .68 2.88
DXS1205 1.93 2.01 1.74 1.25 .58 1.93
DXS1227 1.67 1.80 1.57 1.12 .52 1.93
DXS8043 1.67 1.80 1.57 1.12 .52 1.88
DXS998 2.47 .24 .24 .30 .17 2.03
DXS548 2.47 .24 .24 .30 .17 2.03
Figure 3 The wider pedigree
DXS1001, DXS425, DXS1212, DXS8068, DXS1047,
DXS994, DXS8094, DXS8050, DXS1062, DXS1192,
DXS984, DXS1205, DXS1227, DXS8043, DXS998,
and DXS548.
The map for multipoint analysis was obtained by the
Map program (Collins et al. 1996), which we used to
combine CEPH V8.2–derived pairwise LOD scores with
two-point LODs derived from the pedigree. The inter-
ference parameter in the Rao et al. (1977) map function
was estimated at 0.366, and typing-error frequency
(Shields et al. 1991) was .0012.
We performed multipoint analysis (table 2) by the
LINKMAP option by Vitesse, version 2 (O’Connell and
Weeks 1995), and single-point analysis by MLINK. Pen-
etrances were assumed to be .1, .9, and .9 for the X-
chromosome genotypes dd, dD, and DD in women
(where D is the disease allele) and 0.1 and 0.9 for the
corresponding d and D genotypes in men, because there
were 2 women, among 19 informative transmissions,
who possessed the at-risk haplotype but did not have
ptosis. We estimated allele frequencies for the 21 mark-
ers from the pedigree.
X-chromosome linkage from haplotype analysis
showed evidence for linkage to markers mapped to
Xq24–Xq27.1. A highest single-point LOD score of 2.88
with no recombination was established at DXS1047 and
DXS984 (table 2). The assumption of 100% penetrance
reduced the maximum LOD to 2.71 at withv = 0
DXS1212 and DXS8068. Employing equal allele fre-
quencies gave a single-point LOD of 2.88, implying, as
before, insensitivity to allele frequencies. Recombina-
tions showed the critical region to lie between DXS1001
and DXS1205 (fig. 2). Under these conditions, a LOD
of 2 that uses markers meets the conventional criteria
for X linkage (Terwilliger and Ott 1994). However, this
is conservative since the LODs from both segregation
and marker linkage are independent.
If T represents transmission of disease from fathers
and S is transmission of markers disease transmissiond
and X represents X linkage and autosomal linkage,
—
X
then
P(T dX) P(S dT,X) P(S,T dX) 10 z# = = 2 # 10 .— — —
P(T dX) P(S dT,X) P(S,T dX)
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The LOD is therefore . This provides3.01 2.88 = 5.89
overwhelming evidence for X linkage. Two women, pa-
tients III:5 and III:15, carried the at-risk haplotype but
were unaffected, with no expression of the ptosis
phenotype.
The X-inactivation status of women was investigated
by PCR amplification of a polymorphic site at the human
androgen receptor (HUMAR) locus before and after di-
gestion with methylation-sensitive restriction enzymes
HpaII and CfoI as described by Pegoraro et al. (1994).
PCR products were separated on an ABI 377 sequencer
and quantified by Genescan and Genotyper software
(ABI), and the degree of X inactivation was determined
by comparison of the ratios of the two alleles before and
after restriction and expression of this comparison as a
percentage. We assessed which disease allele was active
by genotyping at a mean average of 8.2 cM between
HUMAR and the disease-interval haplotype. This al-
lowed identification of any recombination between the
inactive allele at HUMAR and the disease interval; it
also allowed us to assess the inactivation status of the
at-risk haplotype.
We analyzed 12 women with the at-risk haplotype in
the pedigree for X-inactivation status at the human an-
drogen receptor locus in DNA from blood. The blood
we analyzed included the blood of the two women (pa-
tients III:5 and III:15) who did not express the ptosis
phenotype. In 8 of 10 affected women, the chromosome
with the mutation was active more often than the normal
chromosome, although in only three patients was the
skew 180%. The remaining two affected women had a
slight skew against activity of the chromosome with the
mutation. Of the two nonexpressing women with the
at-risk haplotype, one, patient III:5, had a unilateral pat-
tern of X inactivation, with the chromosome carrying
the mutation exclusively inactive. This probably explains
her normal phenotype in the presence of the at-risk hap-
lotype. The other, patient III:15, exhibited a random
pattern of X-chromosome inactivation, which does not
explain why the at-risk haplotype does not confer ptosis.
Blood for cytogenetic analysis was obtained from af-
fected individuals II:21 and III:26. Blood lymphocytes
were cultured with conventional techniques. No chro-
mosome abnormalities were identified at the 600-band
level in either individual.
The genetic cause of ptosis in the pedigree studied is
clearly distinct from the only other documented isolated
ptosis pedigree subjected to linkage analysis, as described
by Engle et al. (1997), who found linkage to 1p32-p34.1.
We excluded linkage to chromosome 1 after testing seven
polymorphic markers in the region of interest (table 1)
and demonstrated linkage to Xq24–Xq27.1. Therefore,
this defines a new condition: X-linked dominant con-
genital isolated ptosis. As can be seen from figure 1, the
phenotype is identical in both men and women, making
this an X-linked, truly dominant condition. This is very
unusual, as most X-linked dominant conditions manifest
less severely in women—for example, X-linked Charcot-
Marie-Tooth (MIM 302800) and hypophosphatemia
(vitamin D–resistant rickets [MIM 307800]). More ex-
treme X-linked dominant diseases, such as X-linked
dominant chondroplasia punctata (MIM 302960), are
lethal in men because of their hemizygous state. The
second X chromosome has an ameliorating effect in
women.
That women with Turner syndrome do not have con-
genital isolated ptosis and that ptosis is not common to
all men suggests that the disease is not due to haploin-
sufficiency but, rather, to a dominant negative effect in
carriers of the mutant allele. The locus falls outside the
pseudoautosomal regions, and, therefore, the mutant
allele is likely to be randomly inactivated, although
some nonpseudoautosomal genes escape X-chromosome
inactivation. X-chromosome inactivation studies in
women carrying the at-risk haplotype show that there
is no consistent skewing to favor the expression of the
mutant allele in blood. There is, therefore, no evidence
that the mutant allele affects X-chromosome inactiva-
tion. It may be that the mutant allele overrides the func-
tion of the normal allele at a critical time in neuro-
muscular development, with permanent effects—for
example, by occupation of a significant proportion of
receptors for neurotrophic factors, with a resulting fail-
ure to switch the relevant cell-signaling pathways on or
off.
In conclusion, we have defined X-linked dominant
congenital bilateral isolated ptosis, an X-linked, truly
dominant condition that has not previously been re-
ported. We are not aware of any other X-linked domi-
nant condition with equal expression in men and
women. Linkage for the condition to Xq24–Xq27.1 has
been demonstrated with a single-point LOD score of
2.88 and a cumulative LOD score of 5.89 when com-
bined with a LOD of 3.01 from analyses of the mode
of inheritance from the pedigree alone.
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